Application Nr Approved Date Route Status External Links
NDA020333 None Oral None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Agrylin Is Indicated For The Treatment Of Patients With Thrombocythemia, Secondary To Myeloproliferative Neoplasms, To Reduce The Elevated Platelet Count And The Risk Of Thrombosis And To Ameliorate Associated Symptoms Including Thrombo-Hemorrhagic Events. Agrylin Is A Platelet Reducing Agent Indicated For The Treatment Of Thrombocythemia, Secondary To Myeloproliferative Neoplasms, To Reduce The Elevated Platelet Count And The Risk Of Thrombosis And To Ameliorate Associated Symptoms Including Thrombo-Hemorrhagic Events. ( 1 )

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Anagrelide Hydrochloride ANAGRELIDE HYDROCHLORIDE ZINC3871541

Comments